Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker KPTI
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 4,788 | $0.344 | $1,647 Sale | Form 4 ↗ |
| Sep 1, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 19 | $2.02 | $38.38 Sale | Form 4 ↗ |
| Jul 28, 2026 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 189 | $7.10 | $1,342 Sale | Form 4 ↗ |
| May 14, 2026 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 403 | $9.50 | $3,829 Sale | Form 4 ↗ |
| May 14, 2026 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 408 | $9.50 | $3,876 Sale | Form 4 ↗ |
| May 14, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 324 | $9.50 | $3,078 Sale | Form 4 ↗ |
| May 14, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 53 | $9.50 | $504 Sale | Form 4 ↗ |
| May 14, 2026 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 2,203 | $9.50 | $20.9K Sale | Form 4 ↗ |
| May 14, 2026 | Michael Mano EVP, CLO&Secretary | KPTI Karyopharm Therapeutics Inc. | Sale | 266 | $9.50 | $2,527 Sale | Form 4 ↗ |
| Apr 21, 2026 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 449 | $8.94 | $4,014 Sale | Form 4 ↗ |
| Mar 2, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 559 | $9.41 | $5,260 Sale | Form 4 ↗ |
| Mar 2, 2026 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 5,101 | $9.41 | $48.0K Sale | Form 4 ↗ |
| Mar 2, 2026 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 4,604 | $9.41 | $43.3K Sale | Form 4 ↗ |
| Mar 2, 2026 | Michael Mano EVP, CLO&Secretary | KPTI Karyopharm Therapeutics Inc. | Sale | 3,526 | $9.41 | $33.2K Sale | Form 4 ↗ |
| Mar 2, 2026 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 5,066 | $9.41 | $47.7K Sale | Form 4 ↗ |
| Mar 2, 2026 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 12,361 | $9.41 | $116.3K Sale | Form 4 ↗ |
| Feb 17, 2026 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 378 | $8.63 | $3,262 Sale | Form 4 ↗ |
| Feb 3, 2026 | Lori Macomber EVP, CFO & Treasurer | KPTI Karyopharm Therapeutics Inc. | Sale | 1,626 | $6.30 | $10.2K Sale | Form 4 ↗ |
| Jan 28, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 50 | $7.03 | $352 Sale | Form 4 ↗ |
| Jan 21, 2026 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 265 | $5.96 | $1,579 Sale | Form 4 ↗ |
| Oct 1, 2025 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 362 | $6.30 | $2,281 Sale | Form 4 ↗ |
| Sep 15, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 1,257 | $6.43 | $8,083 Sale | Form 4 ↗ |
| Sep 15, 2025 | Michael Mano SVP, General Counsel&Secretary | KPTI Karyopharm Therapeutics Inc. | Sale | 234 | $6.43 | $1,505 Sale | Form 4 ↗ |
| Sep 15, 2025 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 401 | $6.43 | $2,578 Sale | Form 4 ↗ |
| Sep 15, 2025 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 408 | $6.43 | $2,623 Sale | Form 4 ↗ |
| Sep 15, 2025 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 325 | $6.43 | $2,090 Sale | Form 4 ↗ |
| Sep 15, 2025 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 23 | $6.43 | $148 Sale | Form 4 ↗ |
| Sep 3, 2025 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 12 | $6.78 | $81.36 Sale | Form 4 ↗ |
| Jul 29, 2025 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 191 | $4.37 | $835 Sale | Form 4 ↗ |
| Jul 22, 2025 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 238 | $4.00 | $952 Sale | Form 4 ↗ |
| May 6, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 236 | $7.12 | $1,680 Sale | Form 4 ↗ |
| Apr 23, 2025 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 419 | $6.17 | $2,585 Sale | Form 4 ↗ |
| Apr 4, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 245 | $3.74 | $916 Sale | Form 4 ↗ |
| Mar 4, 2025 | Sohanya Roshan Cheng EVP & Chief Commercial Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 3,445 | $6.29 | $21.7K Sale | Form 4 ↗ |
| Mar 4, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 11,694 | $6.29 | $73.6K Sale | Form 4 ↗ |
| Mar 4, 2025 | Reshma Rangwala EVP & Chief Medical Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 3,587 | $6.29 | $22.6K Sale | Form 4 ↗ |
| Mar 4, 2025 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 3,548 | $6.29 | $22.3K Sale | Form 4 ↗ |
| Mar 4, 2025 | Kristin Abate Chief Accounting Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 571 | $6.29 | $3,592 Sale | Form 4 ↗ |
| Mar 4, 2025 | Michael Mano SVP, General Counsel&Secretary | KPTI Karyopharm Therapeutics Inc. | Sale | 2,793 | $6.29 | $17.6K Sale | Form 4 ↗ |
| Feb 18, 2025 | Stuart Poulton EVP, Chief Development Officer | KPTI Karyopharm Therapeutics Inc. | Sale | 5,914 | $0.63 | $3,726 Sale | Form 4 ↗ |
| Feb 4, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 4,099 | $0.65 | $2,664 Sale | Form 4 ↗ |
| Jan 6, 2025 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 4,055 | $0.78 | $3,163 Sale | Form 4 ↗ |
| Dec 4, 2024 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 3,620 | $0.81 | $2,932 Sale | Form 4 ↗ |
| Nov 5, 2024 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 3,675 | $0.91 | $3,344 Sale | Form 4 ↗ |
| Oct 4, 2024 | Richard A. Paulson President and CEO, Director | KPTI Karyopharm Therapeutics Inc. | Sale | 3,607 | $0.88 | $3,174 Sale | Form 4 ↗ |
45 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances